Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications - Neurodegenerative -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (331)	10/11/2009 11:30:17 PM
From: tnsaf	Respond to of 448

Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity Author Affiliations Departments of aNeurology and Neurological Sciences and Pathology (Neuropathology), Beckman Center for Molecular Medicine Stanford University, Stanford, CA 94305; Department of Neurooncology and German Cancer Research Center, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany; and Department of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, NY 10461 Published online before print August 19, 2009, doi: 10.1073/pnas.0903958106 PNAS September 1, 2009 vol. 106 no. 35 14948-14953 pnas.org Abstract The renin-angiotensin-aldosterone system (RAAS) is a major regulator of blood pressure. The octapeptide angiotensin II (AII) is proteolytically processed from the decapeptide AI by angiotensin-converting enzyme (ACE), and then acts via angiotensin type 1 and type 2 receptors (AT1R and AT2R). Inhibitors of ACE and antagonists of the AT1R are used in the treatment of hypertension, myocardial infarction, and stroke. We now show that the RAAS also plays a major role in autoimmunity, exemplified by multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). Using proteomics, we observed that RAAS is up-regulated in brain lesions of MS. AT1R was induced in myelin-specific CD4+ T cells and monocytes during autoimmune neuroinflammation. Blocking AII production with ACE inhibitors or inhibiting AII signaling with AT1R blockers suppressed autoreactive TH1 and TH17 cells and promoted antigen-specific CD4+FoxP3+ regulatory T cells (Treg cells) with inhibition of the canonical NF-?B1 transcription factor complex and activation of the alternative NF-?B2 pathway. Treatment with ACE inhibitors induces abundant CD4+FoxP3+ T cells with sufficient potency to reverse paralytic EAE. Modulation of the RAAS with inexpensive, safe pharmaceuticals used by millions worldwide is an attractive therapeutic strategy for application to human autoimmune diseases.